AbbVievs.Merck & Co.
ABBV vs MRK · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 1.4× larger than Merck & Co. by market cap; Merck & Co. trades at the lower P/E (34.1 vs 120.6); year to date, Merck & Co. leads (+17.4% vs +8.6%).
Side by side
| ABBV | MRK | |
|---|---|---|
| Market cap | $438B | $305B |
| Price | $248.08 | $123.54 |
| Today | −0.7% | −1.2% |
| Return YTD | +8.6% | +17.4% |
| Return 1Y | +27.2% | +47.0% |
| P/E | 120.6 | 34.1 |
| P/S | 7.0 | 4.6 |
| P/B | 308.7 | 6.7 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AbbVieABBV
Large biopharma with immunology (Skyrizi, Rinvoq), oncology and neuroscience.
Full ABBV profile →Merck & Co.MRK
American pharmaceutical group with strengths in oncology (Keytruda), vaccines and animal health.
Full MRK profile →More comparisons in Big pharma
See where ABBV and MRK sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →